academic article

• Lau DKTay RYYeung YHChionh FMooi JMurone CSkrinos EPrice TJMariadason JMTebbutt NC. Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study.  British Journal of Cancer.  118:966-971. 2018
• Yeung YLau DKChionh FTran HTse JWTWeickhardt AJNikfarjam MScott AMTebbutt NCMariadason JM. K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.  Molecular Oncology.  11:1130-1142. 2017
• Chionh FLau DYeung YPrice TTebbutt N. Oral versus intravenous fluoropyrimidines for colorectal cancer.  The Clinical Respiratory Journal.  2017:1-218. 2017